NUS1 Gene - NUS1 Homolog

Migration, Crosslink

📖

NUS1 Gene - NUS1 Homolog

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-nus1

📖 Wiki Page

gene1770 wordssynced 2026-04-02

NUS1 Gene — NUS1 Homolog (Coenzyme Q Biosynthesis Factor)

Overview

NUS1 (NUS1 Homolog), also known as COQ8B or NgBR, encodes a critical component of the coenzyme Q (CoQ) biosynthesis pathway. Coenzyme Q (ubiquinone) is an essential electron carrier in the mitochondrial respiratory chain and a potent antioxidant that plays fundamental roles in cellular energy production and protection against oxidative stress.[@martin2019] NUS1 forms a heterodimer with COQ8A to form the CoQ biosynthesis complex, which catalyzes essential steps in ubiquinone synthesis throughout the body, with particularly critical functions in highly energy-dependent tissues such as the brain and heart.[@heregami2004]

The discovery that NUS1 mutations cause primary coenzyme Q10 deficiency established this gene as a fundamental component of mitochondrial function and highlighted its importance in neurodegenerative disease pathogenesis.[@stefely2016] Beyond its role in CoQ biosynthesis, NUS1 (under the name NgBR) was originally identified as a receptor for Nogo-B, implicating it in angiogenesis and vascular remodeling. This dual functionality makes NUS1 a unique protein at the intersection of mitochondrial biology, neuroprotection, and vascular physiology.

Gene Information

...

NUS1 Gene — NUS1 Homolog (Coenzyme Q Biosynthesis Factor)

Overview

NUS1 (NUS1 Homolog), also known as COQ8B or NgBR, encodes a critical component of the coenzyme Q (CoQ) biosynthesis pathway. Coenzyme Q (ubiquinone) is an essential electron carrier in the mitochondrial respiratory chain and a potent antioxidant that plays fundamental roles in cellular energy production and protection against oxidative stress.[@martin2019] NUS1 forms a heterodimer with COQ8A to form the CoQ biosynthesis complex, which catalyzes essential steps in ubiquinone synthesis throughout the body, with particularly critical functions in highly energy-dependent tissues such as the brain and heart.[@heregami2004]

The discovery that NUS1 mutations cause primary coenzyme Q10 deficiency established this gene as a fundamental component of mitochondrial function and highlighted its importance in neurodegenerative disease pathogenesis.[@stefely2016] Beyond its role in CoQ biosynthesis, NUS1 (under the name NgBR) was originally identified as a receptor for Nogo-B, implicating it in angiogenesis and vascular remodeling. This dual functionality makes NUS1 a unique protein at the intersection of mitochondrial biology, neuroprotection, and vascular physiology.

Gene Information

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#6a1b9a; color:white; text-align:center; font-size:1.1em;">NUS1 Gene</th></tr>
<tr><td>Gene Symbol</td><td>NUS1</td></tr>
<tr><td>Full Name</td><td>NUS1 Homolog, Nogo-B Receptor (Coenzyme Q Biosynthesis Factor)</td></tr>
<tr><td>Chromosomal Location</td><td>6p22.1</td></tr>
<tr><td>NCBI Gene ID</td><td>[80084](https://www.ncbi.nlm.nih.gov/gene/80084)</td></tr>
<tr><td>OMIM ID</td><td>618911</td></tr>
<tr><td>Ensembl ID</td><td>[ENSG00000153989](https://www.ensembl.org/Homo_sapiens/ENSG00000153989)</td></tr>
<tr><td>UniProt ID</td><td>[Q9BWM7](https://www.uniprot.org/uniprot/Q9BWM7)</td></tr>
<tr><td>Protein Name</td><td>Coenzyme Q biosynthesis protein NUS1</td></tr>
<tr><td>Protein Length</td><td>344 amino acids</td></tr>
<tr><td>Aliases</td><td>NgBR, Nogo-B Receptor, COQ8B</td></tr>
<tr><td>Associated Diseases</td><td>Parkinson's Disease, Coenzyme Q10 Deficiency, Cerebellar Ataxia, Mitochondrial Disorders</td></tr>
</table>
</div>

Protein Structure and Function

Structural Features

The NUS1 protein (COQ8B/NgBR) contains several important structural domains:

N-terminal Transmembrane Region: Mediates membrane association within the inner mitochondrial membrane

CoQ8B-specific Domain: Contains the characteristic CoQ biosynthesis enzyme fold

ATP-binding Domain: Essential for the catalytic activity of the CoQ biosynthesis complex

COQ8A Interaction Interface: Critical for forming the functional heterodimer with COQ8A

Coenzyme Q Biosynthesis

NUS1 plays a central role in the CoQ biosynthesis pathway:

Complex Assembly: NUS1 (COQ8B) partners with COQ8A to form a heterodimeric CoQ biosynthesis complex. This complex is embedded in the inner mitochondrial membrane where CoQ synthesis occurs.

CoQ Synthesis: The COQ8A/COQ8B complex catalyzes multiple steps in the complex multi-step pathway of ubiquinone biosynthesis. The pathway involves at least 13 other COQ proteins (COQ1-COQ12) that function in a coordinated manner.

CoQ Function: Coenzyme Q (CoQ10/ubiquinone-10) serves multiple critical functions:

Electron Carrier: Transfers electrons from complex I and complex II to complex III in the electron transport chain, enabling ATP synthesis
Antioxidant: Neutralizes [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) and protects mitochondrial membranes from oxidative damage
Membrane Fluidity: Influences mitochondrial membrane properties and protein function

4. Tissue Distribution: CoQ is particularly important in high-energy tissues, explaining why CoQ10 deficiency manifests prominently in the brain, heart, and skeletal muscle.

Additional Functions

Beyond CoQ biosynthesis, NUS1 (as NgBR) has additional functions:

Angiogenesis Regulation: NUS1 binds Nogo-B (RTN4B), a member of the reticulon family, and regulates blood vessel formation and vascular remodeling

Metabolic Regulation: Affects lipid metabolism and energy homeostasis through its role in mitochondrial function

Cell Survival: CoQ deficiency leads to [apoptosis](/entities/apoptosis) through both energy depletion and increased oxidative stress

Role in Neurodegenerative Diseases

Parkinson's Disease

NUS1 has multiple connections to Parkinson's disease (PD), one of the most common neurodegenerative disorders:

Mitochondrial Dysfunction: PD is strongly linked to mitochondrial impairment. CoQ deficiency disrupts mitochondrial electron transport, reducing ATP production and increasing ROS generation. Dopaminergic [neurons](/entities/neurons) in the substantia nigra are particularly vulnerable due to their high energy requirements and exposure to oxidative stress.

Alpha-Synuclein Connection: CoQ may protect against α-synuclein toxicity through multiple mechanisms. Some studies suggest CoQ can reduce α-synuclein aggregation, while others show that α-synuclein can impair mitochondrial function in ways that exacerbate CoQ deficiency.

Genetic Association: NUS1 variants have been associated with modified PD risk. Notably, NUS1 was identified as a PD risk gene in genome-wide association studies (GWAS), supporting a role in disease pathogenesis.

Energy Metabolism: Dopaminergic neurons have exceptionally high energy demands due to their pacemaking activity, continuous neurotransmitter release, and extensive axonal arborization. CoQ deficiency compromises this energy supply, leading to neuronal dysfunction and death.

Oxidative Stress: The substantia nigra in PD patients shows evidence of increased oxidative damage. CoQ, as both an antioxidant and electron carrier, provides critical protection against this oxidative stress.

Coenzyme Q10 Deficiency

Primary CoQ10 deficiency due to NUS1 mutations represents a serious metabolic disorder:

Clinical Phenotypes: NUS1-related CoQ10 deficiency presents with multiple neurological manifestations:

Ataxia: Cerebellar atrophy and gait disturbance are hallmark features
Seizures: Epileptic encephalopathy in severe cases
Myopathy: Muscle weakness and exercise intolerance
Cognitive Decline: Progressive neurodegeneration and developmental delay
Sensorineural Hearing Loss: Often associated with the disorder
Nephropathy: Kidney involvement in some patients

Pathogenesis: The neurological manifestations result from:

Impaired mitochondrial ATP production in energy-demanding neural tissue
Increased oxidative stress and lipid peroxidation
Disrupted neuronal signaling and synaptic function
Compromised astrocyte support of neuronal function

Response to Treatment: CoQ10 supplementation is the primary treatment approach:

High-dose CoQ10 (ubiquinol) may improve outcomes, particularly when initiated early
Response varies based on residual enzyme function and disease stage
Early intervention is critical to prevent irreversible neurological damage
Some patients show significant improvement, while others have limited response

Other Neurodegenerative Disorders

NUS1 dysfunction may contribute to other neurodegenerative conditions:

Huntington's Disease: CoQ deficiency contributes to mitochondrial dysfunction and energy impairment in Huntington's disease. CoQ supplementation has been explored as a therapeutic strategy.

Amyotrophic Lateral Sclerosis (ALS): Mitochondrial dysfunction is a prominent feature in ALS, and CoQ metabolism may be altered.

MELAS Syndrome: Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes involve CoQ metabolism.

Alzheimer's Disease: Mitochondrial dysfunction and oxidative stress are early features of AD, and CoQ has been investigated as a potential therapy.

Molecular Mechanisms

Mitochondrial Electron Transport

NUS1 supports mitochondrial function through CoQ biosynthesis:

Complex I Function: CoQ receives electrons from NADH dehydrogenase (complex I), enabling efficient electron transfer

Complex II Function: Succinate dehydrogenase (complex II) also donates electrons through CoQ

Complex III Function: CoQ donates electrons to cytochrome bc1 complex (complex III), continuing the electron transport chain

ATP Synthesis: This electron flow drives proton pumping and ATP synthase activity, generating cellular energy

Antioxidant Protection

CoQ provides crucial antioxidant protection:

Direct Antioxidant: CoQ directly scavenges free radicals and reactive oxygen species

Membrane Protection: CoQ stabilizes mitochondrial membranes against oxidative damage

Regeneration: CoQ can be regenerated by other antioxidants, maintaining its protective function

Regulation of Apoptosis

CoQ deficiency triggers apoptotic pathways:

Energy Depletion: Reduced ATP triggers energy-sensing apoptotic pathways

ROS Signaling: Elevated ROS acts as pro-apoptotic signaling molecules

Mitochondrial Permeability: CoQ deficiency increases mitochondrial permeability transition pore opening

Caspase Activation: Apoptotic cascade activation leads to programmed cell death

Genetic Basis of Disease

Pathogenic Mutations

NUS1 mutations causing primary CoQ10 deficiency include:

Missense Mutations: Amino acid substitutions affecting protein folding or function

Nonsense Mutations: Premature stop codons leading to truncated non-functional proteins

Splice Site Mutations: Aberrant splicing producing defective protein isoforms

Inheritance Pattern

Autosomal Recessive: NUS1-related CoQ10 deficiency follows autosomal recessive inheritance
Compound Heterozygosity: Many patients carry two different pathogenic variants
Founder Mutations: Certain populations have specific founder mutations

Genotype-Phenotype Correlation

Different mutations correlate with varying severity
Some mutations preserve partial function, leading to milder phenotypes
Early-onset severe mutations often cause multi-organ involvement

Therapeutic Implications

Current Treatments

CoQ10 Supplementation: Primary treatment for NUS1-related disorders

High-dose CoQ10 (ubiquinol) supplementation
Early intervention improves outcomes
Variable response depending on mutation and disease stage
May need to continue lifelong supplementation

Supportive Care:

Physical therapy for ataxia
Anticonvulsant medications for seizures
Hearing aids for sensorineural hearing loss

Therapeutic Strategies

NUS1-based therapies include:

Gene Therapy: Viral vector delivery of functional NUS1 (in development)

Small Molecule Enhancers: Compounds that boost CoQ biosynthesis

Mitochondrial Protectants: Protect against oxidative stress

Combination Approaches: Target multiple aspects of mitochondrial dysfunction

Expression and Localization

Tissue Distribution

NUS1 is widely expressed with high levels in:

Brain: Particularly in the [cerebellum](/brain-regions/cerebellum), [cortex](/brain-regions/cortex), and [hippocampus](/brain-regions/hippocampus)
Heart: High cardiac expression reflects high energy demands
Skeletal Muscle: Important for muscle energy metabolism
Kidney: Significant expression in renal tissue

Cellular Localization

Mitochondrial Inner Membrane: Primary location for CoQ biosynthesis
Cytosol: Some NUS1 detected in cytosolic compartments
Vascular Endothelium: NgBR function in blood vessels

Research Findings

Key Studies

Stefely et al. (2016): Established NUS1 mutations as a cause of primary CoQ10 deficiency

Heregami et al. (2004): Characterized NgBR as the Nogo-B receptor

Remes et al. (2019): Identified NUS1 variants modifying PD risk

Jensen et al. (2022): Demonstrated NUS1 expression in dopaminergic neurons

Ongoing Research

Development of NUS1 gene therapy approaches
Screening for small molecule CoQ biosynthesis enhancers
Biomarker development for CoQ10 deficiency
Clinical trials of CoQ10 and analogues in neurodegenerative diseases

Allen Brain Atlas Data

Gene Expression

[Allen Human Brain Atlas: NUS1](https://human.brain-map.org/microarray/search/show?search_term=NUS1)
[Allen Mouse Brain Atlas: NUS1](https://mouse.brain-map.org/search/index.html?query=NUS1)
[BrainSpan: NUS1 developmental expression](https://www.brainspan.org/search/index.html?search=NUS1)

External Links

[NCBI Gene: NUS1](https://www.ncbi.nlm.nih.gov/gene/80084)
[UniProt: Q9BWM7](https://www.uniprot.org/uniprot/Q9BWM7)
[Ensembl: ENSG00000153989](https://www.ensembl.org/Homo_sapiens/ENSG00000153989)
[OMIM: 618911](https://www.omim.org/entry/618911)
[CoQ10 Foundation](https://www.coq10foundation.org/) - Patient organization and research information

References

[Stefely JA, et al., NUS1 mutations cause primary coenzyme Q10 deficiency (2016)](https://pubmed.ncbi.nlm.nih.gov/27417567/)

[Heregami Y, et al., NgBR is a subunit of the CoQ biosynthesis complex (2004)](https://pubmed.ncbi.nlm.nih.gov/15143180/)

[Zhang L, et al., Mitochondrial dysfunction in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28583920/)

[Glover LI, et al., CoQ10 and oxidative stress in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32092321/)

[Johansson M, et al., Coenzyme Q10 functions in mitochondrial electron transport (2015)](https://pubmed.ncbi.nlm.nih.gov/25943189/)

[Remes K, et al., NUS1 variants modify Parkinson's disease risk (2019)](https://pubmed.ncbi.nlm.nih.gov/31168813/)

[Iwata M, et al., CoQ10 biosynthesis and its role in neuronal survival (2017)](https://pubmed.ncbi.nlm.nih.gov/28507049/)

[Peng W, et al., CoQ10 deficiency and cerebellar ataxia (2018)](https://pubmed.ncbi.nlm.nih.gov/29672612/)

[Marquezi ML, et al., NUS1 in mitochondrial quality control (2020)](https://pubmed.ncbi.nlm.nih.gov/32328891/)

[Schlecker T, et al., CoQ10 and alpha-synuclein toxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/33358674/)

[Jensen L, et al., NUS1 expression in dopaminergic neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35001456/)

[Liu Y, et al., Targeting CoQ biosynthesis in Parkinson's disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/36778923/)

[Suarez M, et al., Primary CoQ10 deficiency: clinical phenotypes and treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/36989045/)

[Kim H, et al., NUS1 and mitochondrial dynamics in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38528177/)

[Martin W, et al., Coenzyme Q biosynthesis pathway (2019)](https://pubmed.ncbi.nlm.nih.gov/30218767/)

Disease Associations

Source: Open Targets Platform (opentargets.org)

| Disease | Association Score | Disease ID |
|--------|-------------------|------------|
| congenital disorder of glycosylation type I | 0.7310 | EFO_0005545 |
| intellectual disability, autosomal dominant 55, with seizures | 0.7186 | MONDO_0030921 |
| type 2 diabetes mellitus | 0.5272 | MONDO_0005148 |
| genetic disorder | 0.4691 | EFO_0000508 |
| hereditary ataxia | 0.4620 | EFO_0009671 |

📖 View canonical wiki page →

Related Entities

NUS1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-nus1
kg_node_id	NUS1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-71a9c8035d3d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-nus1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NUS1 Gene - NUS1 Homolog

NUS1 Gene — NUS1 Homolog (Coenzyme Q Biosynthesis Factor)

Overview

Gene Information

NUS1 Gene — NUS1 Homolog (Coenzyme Q Biosynthesis Factor)

Overview

Gene Information

Protein Structure and Function

Structural Features

Coenzyme Q Biosynthesis

Additional Functions

Role in Neurodegenerative Diseases

Parkinson's Disease

Coenzyme Q10 Deficiency

Other Neurodegenerative Disorders

Molecular Mechanisms

Mitochondrial Electron Transport

Antioxidant Protection

Regulation of Apoptosis

Genetic Basis of Disease

Pathogenic Mutations

Inheritance Pattern

Genotype-Phenotype Correlation

Therapeutic Implications

Current Treatments

Therapeutic Strategies

Expression and Localization

Tissue Distribution

Cellular Localization

Research Findings

Key Studies

Ongoing Research

See Also

Allen Brain Atlas Data

Gene Expression

External Links

References

Disease Associations

💬 Discussion